Negreanu Lucian, Babiuc Ruxandra, Bengus Andreea, Sadagurschi Roxana
Lucian Negreanu, Ruxandra Babiuc, Andreea Bengus, Roxana Sadagurschi, Internal Medicine 2 Gastroenterology Department, University Hospital, Carol Davila University of Medicine Bucharest, 011465 Bucharest, Romania.
World J Gastrointest Endosc. 2013 Nov 16;5(11):559-67. doi: 10.4253/wjge.v5.i11.559.
To assess the feasibility, accuracy and acceptability of PillCam Colon 2 in detection of significant lesions in colorectal cancer risk patients, unable or unwilling to perform colonoscopy.
This is a prospective, single center study using the second generation of PillCam Colon capsule. In all patients the readers were instructed to review the entire colon capsule endoscopy (CCE) examination using Rapid 7 software and additionally to note significant extra-colonic findings. Colonic significant findings were described according to European Society of Gastrointestinal Endoscopy guidelines. CCE procedure completion rate, level of bowel preparation and rate of adverse events were assessed.
A total of 70 patients at risk of colorectal cancer were enrolled in the study. In three patients the procedure failed because the capsule was not functioning when entered the colon. PillCam Colon 2 showed positive findings in 23 (34%, 95%CI: 21.6%-44.1%) of the remaining 67 patients. Six patients were diagnosed with tumors: 4 with colon cancers, 1 with gastric cancer and 1 with a small bowel cancer. The capsule findings were confirmed after surgery in all these patients. The capsule excretion rate in twelve hours was 77% with 54 patients having a complete examination. The rectum was not explored during CCE procedure, in 16 patients (23%, 95%CI: 13.7%-34.1%). Every patient accepted CCE as an alternative exploration tool and 65/70 (93%) agreed to have another future control by CCE. No complications were reported during or after CCE examination.
PillCam Colon 2 capsule was effective in detecting significant lesions and might be considered an adequate alternative diagnostic tool in patients unable or unwilling to undergo colonoscopy.
评估结肠胶囊内镜2（PillCam Colon 2）在检测结直肠癌风险患者中重大病变的可行性、准确性和可接受性，这些患者无法或不愿接受结肠镜检查。
这是一项使用第二代结肠胶囊内镜的前瞻性单中心研究。在所有患者中，要求阅片者使用Rapid 7软件回顾整个结肠胶囊内镜（CCE）检查，并额外记录重大的结肠外发现。结肠重大发现根据欧洲胃肠内镜学会指南进行描述。评估CCE程序完成率、肠道准备水平和不良事件发生率。
共有70例结直肠癌风险患者纳入研究。3例患者检查失败，原因是胶囊进入结肠时未正常工作。在其余67例患者中，结肠胶囊内镜2显示阳性发现的有23例（34%，95%CI：21.6%-44.1%）。6例患者被诊断为肿瘤：4例为结肠癌，1例为胃癌，1例为小肠癌。所有这些患者术后均证实了胶囊检查结果。12小时内胶囊排出率为77%，54例患者完成了完整检查。在CCE检查过程中，16例患者（23%，95%CI：13.7%-34.1%）的直肠未被探查。每位患者都接受CCE作为一种替代检查工具，65/70（93%）的患者同意未来再次接受CCE检查。CCE检查期间及之后均未报告并发症。
结肠胶囊内镜2在检测重大病变方面有效，对于无法或不愿接受结肠镜检查的患者，可被视为一种合适的替代诊断工具。
